DrugPatentWatch Database Preview
IONSYS Drug Profile
Which patents cover Ionsys, and when can generic versions of Ionsys launch?
This drug has one hundred and seventy-five patent family members in thirty-three countries.
The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fentanyl hydrochloride profile page.
Summary for IONSYS
International Patents: | 175 |
US Patents: | 12 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 9 |
Clinical Trials: | 6 |
Patent Applications: | 54 |
Formulation / Manufacturing: | see details |
Drug Prices: | see details |
DailyMed Link: | IONSYS at DailyMed |

Pharmacology for IONSYS
Drug Class | Opioid Agonist |
Mechanism of Action | Full Opioid Agonists |
Synonyms for IONSYS
1-(2-Phenylethyl)-4-(N-propananilido)piperidine |
1-Phenethyl-4-(N-phenylpropionamido)piperidine |
1-Phenethyl-4-N-propionylanilinopiperidine |
437-38-7 |
5-22-08-00049 (Beilstein Handbook Reference) |
80832-90-2 |
9235-EP2275420A1 |
9235-EP2277861A1 |
9235-EP2277875A2 |
9235-EP2280008A2 |
9235-EP2298764A1 |
9235-EP2298765A1 |
9235-EP2298768A1 |
9235-EP2305652A2 |
9235-EP2305654A1 |
9235-EP2308509A1 |
9235-EP2308872A1 |
9235-EP2314585A1 |
9235-EP2314590A1 |
9235-EP2316829A1 |
990-73-8 (citrate) |
Abstral |
AC1L1FQ2 |
ACN-S001735 |
Actiq |
AK116449 |
API0002693 |
BDBM50008984 |
BIDD:GT0555 |
BRN 0494484 |
CAS-437-38-7 |
CF0052 |
CHEBI:119915 |
CHEMBL596 |
CS-7211 |
CTK8G2863 |
D00320 |
D09ISU |
D0E1WI |
DB00813 |
DSSTox_CID_3049 |
DSSTox_GSID_23049 |
DSSTox_RID_76851 |
DTXSID9023049 |
Duragesic |
Duragesic (TN) |
Duragesic-100 |
Duragesic-12 |
Duragesic-25 |
Duragesic-50 |
Duragesic-75 |
Durogesic |
Durotep MT |
effentora |
EINECS 207-113-6 |
Epitope ID:153507 |
Fentanest |
Fentanil |
Fentanil [DCIT] |
Fentanila |
Fentanila [INN-Spanish] |
Fentanilo |
fentanyl |
Fentanyl (JAN/USAN/INN) |
fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals |
Fentanyl [INN:BAN] |
Fentanyl [USAN:USP:INN:BAN] |
Fentanyl 0.1 mg/ml in Methanol |
Fentanyl 1.0 mg/ml in Methanol |
Fentanyl buccal |
Fentanyl CII |
Fentanyl solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
Fentanyl solution, 100 mug/mL in methanol, ampule of 1 mL, certified reference material |
Fentanyl Transdermal System |
Fentanyl-100 |
Fentanyl-12 |
Fentanyl-25 |
Fentanyl-37 |
Fentanyl-50 |
Fentanyl-62 |
Fentanyl-75 |
Fentanyl-87 |
FENTANYL-HCl |
Fentanylum |
Fentanylum [INN-Latin] |
Fentora |
FT-0668508 |
GTPL1626 |
HE006416 |
HE343370 |
HE343371 |
HSDB 3329 |
HY-U00158 |
Instanyl |
JNS020QD |
L001275 |
Lazanda |
LS-124439 |
Matrifen |
N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide |
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide |
N-(1-Phenethyl-4-piperidyl)propionanilide |
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide |
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide(Fentanyl) |
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide |
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide |
N-(1-Phenylethyl-4-piperidinyl)propionanilide |
N-Phenethyl-4-(N-propionylanilino)piperidine |
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide |
N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide # |
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide |
NCGC00168252-01 |
Oprea1_152073 |
Oprea1_207148 |
pain therapy (transmucosal film), Auxilium Pharmaceuticals |
PDSP1_000860 |
PDSP2_000846 |
PecFent |
Phentanyl |
PJMPHNIQZUBGLI-UHFFFAOYSA-N |
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- |
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI) |
Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]- |
Propionanilide, N-(1-phenethyl-4-piperidyl)- |
R 4263 |
R4263 |
SCHEMBL8804 |
Sentonil |
Sublimase |
Sublimaze |
Subsys |
Subsys (TN) |
Tox21_112611 |
UF599785JZ |
UNII-UF599785JZ |
ZINC2522669 |
US Patents and Regulatory Information for IONSYS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for IONSYS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | ➤ Sign Up | ➤ Sign Up |
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | ➤ Sign Up | ➤ Sign Up |
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | ➤ Sign Up | ➤ Sign Up |
The Medicines Co | IONSYS | fentanyl hydrochloride | SYSTEM;IONTOPHORESIS, TRANSDERMAL | 021338-001 | May 22, 2006 | ➤ Sign Up | ➤ Sign Up |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for IONSYS
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
7,054,683 | Methods of electrotransport drug delivery | ➤ Sign Up |
9,645,179 | Self-test for analgesic product | ➤ Sign Up |
6,317,629 | Iontophoretic drug delivery apparatus | ➤ Sign Up |
6,505,069 | Electrochemically reactive cathodes for an electrotransport device | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents for IONSYS
Supplementary Protection Certificates for IONSYS
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
0653 | Netherlands | ➤ Sign Up | PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906 |
2011000009 | Germany | ➤ Sign Up | PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831 |
2006000022 | Germany | ➤ Sign Up | PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126 |
2014000024 | Germany | ➤ Sign Up | PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |